BAALC expression as a diagnostic marker for acute leukemia
AssigneeThe Ohio State University Research Foundation
InventorsStephan Markus Tanner, Albert de la Chapelle
Life of this patent
Estimating the term…
Abstract
Overexpression of the gene, BAALC, in biological samples from a patient is prognostic for tumor aggressiveness and unfavorable patient outcome. The present invention provides polynucleotide primers and probes for assaying for overexpression of BAALC transcripts. Kits containing the primers and probes are also provided. Also provided are antibodies for assaying for overexpression of BAALC proteins as well as peptide immunogens for producing the anti-BAALC antibodies. The present invention also provides methods for characterizing acute myelogenous leukemia, chronic myelogenous leukemia and prostate cancer in a patient, base on detection of BAALC overexpression.
Claims27
A method for characterizing acute myelogenous leukemia (AML) in a patient with AML, comprising assaying for overexpression of one or more BAALC transcripts in cells obtained from the patient, wherein overexpression of one or more BAALC transcripts in cells of the patient indicates that the patient has an aggressive form of AML.
A method for characterizing acute myelogenous leukemia (AML) in a patient with AML, comprising:
- assaying for overexpression of a polypeptide encoded by one or more BAALC gene transcripts in cells obtained from the patient, wherein overexpression of the polypeptide in cells of the patient indicates that the patient has an aggressive form of AML.
A kit for characterizing AML, chronic myelogenous leukemia (CML), or prostate cancer in a patient, said kit comprising:
- a primer set comprising a forward primer comprising a sequence that is identical to a first region in a BAALC transcript and a reverse primer comprising a sequence that is the reverse complement of a second region in a BAALC transcript, wherein said forward primer and said reverse primer are each from 10 to 50 nucleotides in length.
A polynucleotide probe for characterizing AML, CML or prostate cancer in a patient, wherein said probe comprises a sequence that is complementary to a sequence in exon 1, exon 6, exon 8, or a sequence that spans the exon 6 and exon 8 splice site of a BAALC transcript.
An isolated polynucleotide comprising a sequence selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5 SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, and combinations thereof.
An antibody that is immunospecific for one or more polypeptides that are encoded by a transcript of the BAALC gene.
A method for characterizing prostate cancer in a patient, comprising assaying for overexpression of one or more BAALC polypeptides in a prostate tissue sample obtained from the patient, wherein overexpression of one or more BAALC polypeptides in cells of the patient's prostate indicates that the patient has prostate cancer or an advanced stage of prostate cancer.
A method for characterizing chronic myelogenous leukemia (CML) in a patient with CML, comprising assaying for overexpression of one or more BAALC transcripts in cells obtained from the patient, wherein overexpression of one or more BAALC transcripts in cells of the patient indicates that the patient is in blast crises.
Dependencies are inferred from the claim text.